Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 1:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 178 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cognition in Schizophrenia Clear all
Completed Phase 1 Interventional

Oxytocin Treatment of Social Cognitive and Functional Deficits in Schizophrenia

NCT01394471
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Intranasal Oxytocin Spray
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 11, 2015 · Synced Oct 2, 2026, 1:05 PM EDT
Terminated Not applicable Interventional Results available

Repetitive TMS & Cognitive Training in Adults With Schizophrenia

NCT03741751
View directory record Official record
Conditions
Schizophrenia Spectrum and Other Psychotic Disorders, Cognitive Impairment
Interventions
rTMS, Computerized cognitive training
Device · Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 2, 2026, 1:05 PM EDT
Completed Not applicable Interventional Results available

Nicotinic Enhancement of Cognitive Remediation Training in Schizophrenia

NCT02069392
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Cognitive remediation training, Nicotine polacrilex lozenge
Behavioral · Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 60 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Oct 2, 2026, 1:05 PM EDT
Completed Phase 1 Interventional

Add On Treatment for Cognitive Deficits in Schizophrenia

NCT01346163
View directory record Official record
Conditions
Schizophrenia
Interventions
PF 03654746, Placebo
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 40 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 2, 2011 · Synced Oct 2, 2026, 1:05 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform

NCT02431702
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders
Interventions
Aripiprazole, Haloperidol, Olanzapine, Oral Paliperidone ER, Perphenazine, Quetiapine, Oral Risperidone, Paliperidone Palmitate Injection (PP1M), Paliperidone Palmitate Injection (PP3M)
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 35 Years
Enrollment
337 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
34
States / cities
Little Rock, Arkansas • Garden Grove, California • Lemon Grove, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 2, 2026, 1:05 PM EDT
Completed Phase 1Phase 2 Interventional

Adapted Cognitive/Affective Remediation for Cannabis Misuse in Schizophrenia

NCT01292577
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
CET/PT, Treatment as Usual
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 13, 2020 · Synced Oct 2, 2026, 1:05 PM EDT
Completed Phase 3 Interventional Results available

Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)

NCT04846881
View directory record Official record
Conditions
Schizophrenia
Interventions
Iclepertin, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 50 Years
Enrollment
611 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
20
States / cities
Bellflower, California • Costa Mesa, California • Long Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Oct 2, 2026, 1:05 PM EDT
Completed Phase 3 Interventional

Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

NCT01716975
View directory record Official record
Conditions
Schizophrenia, Impaired Cognition
Interventions
EVP-6124, Placebo
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
767 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
49
States / cities
Phoenixville, Arizona • Little Rock, Arkansas • Cerritos, California + 46 more
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Oct 2, 2026, 1:05 PM EDT
Recruiting Not applicable Interventional

Impact of Cerebellar TMS on Brain and Cognitive Functions in Schizophrenia: a Pilot Study

NCT05389787
View directory record Official record
Conditions
Schizophrenia, Cerebellar Function, Condition
Interventions
Transcranial Magnetic Stimulation
Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 2, 2026, 1:05 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effects of Nicotine on Cognition in Schizophrenia

NCT00383747
View directory record Official record
Conditions
Schizophrenia
Interventions
Transdermal Nicotine Patch
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Oct 2, 2026, 1:05 PM EDT
Completed Phase 4 Interventional Results available

Varenicline Adjunctive Treatment in Schizophrenia

NCT00492349
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
Varenicline, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 60 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
3
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 5, 2022 · Synced Oct 2, 2026, 1:05 PM EDT
Terminated Not applicable Interventional Results available

Non-Invasive Direct Current Stimulation for Cognition in Schizophrenia

NCT02739347
View directory record Official record
Conditions
Schizophrenia, Psychosis
Interventions
Active Trans-cranial direct-current stimulation, Sham Trans-cranial direct current stimulation
Device
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 7, 2022 · Synced Oct 2, 2026, 1:05 PM EDT
Terminated Phase 4 Interventional Results available

Assessing the Effects of Fanapt® on Social Cognition in Schizophrenia

NCT01929889
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Iloperidone
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 10, 2015 · Synced Oct 2, 2026, 1:05 PM EDT
Recruiting Phase 2 Interventional

Study of ALTO-101 in Patients With Schizophrenia

NCT06502964
View directory record Official record
Conditions
Schizophrenia, Cognitive Impairment
Interventions
ALTO-101, ALTO-101 Transdermal Delivery System, Placebo, Placebo Transdermal Delivery System
Drug · Device
Lead sponsor
Alto Neuroscience
Industry
Eligibility
21 Years to 55 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
14
States / cities
Garden Grove, California • Los Angeles, California • Orange, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Oct 2, 2026, 1:05 PM EDT
Completed Not applicable Interventional

Improving Cognition Via Exercise in Schizophrenia

NCT03270098
View directory record Official record
Conditions
Schizophrenia and Related Disorders
Interventions
Aerobic Exercise, Stretching and Toning Exercise
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 55 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
4
States / cities
Stanford, California • Augusta, Georgia • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2023 · Synced Oct 2, 2026, 1:05 PM EDT
Completed Phase 2 Interventional Results available

Fingolimod in Schizophrenia Patients

NCT01779700
View directory record Official record
Conditions
Schizophrenia
Interventions
Fingolimod, placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 2, 2026, 1:05 PM EDT
Completed Not applicable Interventional

A Comparison of Two Cognitive Batteries in People With Schizophrenia

NCT00499044
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
CDR Computerized Cognitive Assessment System, MATRICS Consensus Cognitive Battery
Other
Lead sponsor
North Suffolk Mental Health Association
Other
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 26, 2009 · Synced Oct 2, 2026, 1:05 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Clonazepam Effects on Brain Oscillations and Cognition in Schizophrenia

NCT03061136
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
Clonazepam, Placebo
Drug
Lead sponsor
Palo Alto Veterans Institute for Research
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 2, 2026, 1:05 PM EDT
Completed Not applicable Interventional Results available

Evaluating Two Types of Cognitive Training in Veterans With Schizophrenia

NCT01891721
View directory record Official record
Conditions
Schizophrenia
Interventions
Brain Fitness Program (BFP), Cognitive Package (Cogpack), Commercial Computer Games (Sporcle)
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
25 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Los Angeles, California • West Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Oct 2, 2026, 1:05 PM EDT
Withdrawn Phase 4 Interventional

Once Weekly D-cycloserine for Schizophrenia

NCT00964041
View directory record Official record
Conditions
Schizophrenia
Interventions
D-cycloserine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 20, 2013 · Synced Oct 2, 2026, 1:05 PM EDT
Completed Phase 4 Interventional Results available

Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia

NCT00176423
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
galantamine
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 60 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Oct 2, 2026, 1:05 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia

NCT07191483
View directory record Official record
Conditions
Cognitive Impairment Associated With Schizophrenia (CIAS)
Interventions
KYN-5356 low dose, Placebo, KYN-5356 Medium Dose, KYN-5356 High Dose
Drug · Other
Lead sponsor
Kynexis B.V.
Industry
Eligibility
18 Years to 55 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
15
States / cities
Little Rock, Arkansas • Cerritos, California • Lemon Grove, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 2, 2026, 1:05 PM EDT
Completed Phase 2 Interventional Results available

Oxytocin and Social Cognition in Schizophrenia

NCT00884897
View directory record Official record
Conditions
Social Cognition, Social Anxiety, Emotional Intelligence
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Oct 2, 2026, 1:05 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Modafinil for Treatment of Cognitive Dysfunction in Schizophrenia

NCT00423943
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
modafinil, Placebos
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 54 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2017 · Synced Oct 2, 2026, 1:05 PM EDT